Eddingpharm acquires most ACT assets including telatinib
This article was originally published in Scrip
Executive Summary
In the latest in a string of licensing deals over the past six months, the Chinese firm Eddingpharm has acquired most of the pipeline assets of the private US venture ACT Biotech, including its lead Phase III-ready molecule for stomach cancer.
You may also be interested in...
EOC Gears To Evolve Into Integrated Oncology Company
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Need a specific report? 1000+ reports available
Buy Reports